Nvidia’s $20 billion strategic licensing deal with Groq represents one of the first clear moves in a four-front fight over ...
The FDA has approved inebilizumab-cdon (Uplizna, Amgen) for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody positive generalized myasthenia gravis, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback